iECURE
John Blackwell has a diverse and extensive background in quality assurance and compliance. John has held various leadership roles in different companies, including pharmaceutical, biotech, and agriculture sectors. At iECURE, Inc., they currently serve as the VP of Quality and Compliance. In their previous role as the Head of Quality at Imvax, Inc., they were responsible for ensuring quality standards. At WuXi AppTec, Laboratory Testing Division, as the Senior Director of Testing Operations, they managed a team of scientists and oversaw testing operations. John has also held roles as a Director of Quality Assurance at Cutanea Life Sciences, Inc., Director of Quality Assurance/Quality Control at Bayer, and Director of Analytical Development at Patheon. John has experience with analytical development, analytical sciences, and managing Quality Control departments. Additionally, they have experience in organic produce production and animal management at Annie's Acres. Earlier in their career, they worked at Sanofi Pasteur as Deputy Director and Director of Quality Control, overseeing Quality Control activities and managing a QC laboratory. Prior to that, they worked at Rhodia ChiRex as Manager of QC and Process Separations, where they built and managed a cGMP compliant Quality Control laboratory. Overall, John’s work experience showcases their expertise in quality management, analytical sciences, and leadership in various industries.
John Blackwell earned a BS in Chemistry from the University of Minnesota in 1985. John then pursued a Ph.D. in Analytical Chemistry specializing in Chromatography at the same university, completing it in 1991.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.